A drug against Covid-19 developed at the Federal University of Minas Gerais (UFMG) and the Oswaldo Cruz Foundation (Fiocruz) will begin testing with a group of 432 volunteers, it was announced Monday.
21.01.2022 - CHENGDU, China, Jan. 21, 2022 (GLOBE NEWSWIRE) - Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that final . Seite 1
Clover's COVID-19 Vaccine Candidate Administered as Heterologous Booster in Investigator-Led Phase 2 Clinical Trial forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.
26.11.2021 - The Phase 2 trial will evaluate SCB-2019 (CpG 1018/Alum) as a booster dose in individuals previously vaccinated with CoronaVac or recombinant Covid-19 vaccine (AstraZeneca/Fiocruz) The Phase 2 trial is an investigator initiated study, sponsored by . Seite 1